Date post: | 28-Dec-2015 |
Category: |
Documents |
Upload: | geoffrey-goodwin |
View: | 216 times |
Download: | 0 times |
First Alumni EveningFaculty of Health & Social
CareProfessor Gordon C WishartVisiting Professor of Cancer
SurgeryAnglia Ruskin University
Cambridge Breast Unit
Job Description
• Consultant Breast & Endocrine Surgeon• Director of Breast Services at Cambridge
Breast Unit, Addenbrooke’s Hospital.• Associate Lecturer at Cambridge University• Visiting Professor of Cancer Surgery, Anglia
Ruskin University
TrainingMB ChB (Edinburgh) July 1983
FRCS I (Glasgow) Jan 1986FRCS II (Glasgow) May 1987
MD (Edinburgh) June 1992
FRCS III (Intercollegiate) Jan1995
FRCS (Eng.) June 2001MA (Cantab.) July 2006
10 year all-cause survival probability 80.3% (77.1%, 83.3%)at mean age at diagnosis of 59.1 years and mean NPI of 4.22
10 year all-cause survival probability at mean age of diagnosis 59.1 yearsEPG 89.4% (87.6%, 91.2%)GPG 89.4% (87.6%, 91.2%)MPG1 87.0% (84.8%, 89.2%)MPG2 69.7% (65.2%, 74.2%)PPG 59.1% (53.5%, 64.7%)VPG 33.5% (26.9%, 40.0%)
Cambridge Breast Cancer Research Unit• £2 million raised from charitable
donors• Opened August 2009• Clinical research• Supports translational research
programme• Consulting rooms, imaging rooms,
laboratory, meeting rooms.
Clinical studies• Diagnostics: Infrared imaging, BT blood
test, elastography, tomosynthesis, axillary assessment of axilla
• Neoadjuvant chemo: NeoTanGo, Artemis
• Neoadjuvant endocrine: MONET, Artist• RT: IMPORT Low, mammosite• Targeted therapy: persephone
Research programmes
• Genetic epidemiology of predisposition and survival• Molecular classification, prognostic and predictive markers• Molecular pathology• Adult breast stem cell programme• Systemic and radiation therapy clinical trials• Cancer imaging for improved diagnosis and response to therapy
monitoring• Therapy monitoring with CTCs• Novel therapeutics (drug development)